Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, May 22, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vernon Bernardino Reiterated (CADL) at Strong Buy and Held Target at $11 on, May 22nd, 2023
Vernon Bernardino of HC Wainwright & Co., Reiterated "Candel Therapeutics, Inc." (CADL) at Strong Buy and Held Target at $11 on, May 22nd, 2023.
Vernon has made no other calls on CADL in the last 4 months.
There are 2 other peers that have a rating on CADL. Out of the 2 peers that are also analyzing CADL, 0 agree with Vernon's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vernon
- Evan David Seigerman of "BMO Capital" Maintained at Buy with Decreased Target to $3 on, Monday, May 15th, 2023
- Judah Frommer of "Credit Suisse" Maintained at Buy with Decreased Target to $7 on, Friday, March 31st, 2023
